Dual PI3K/mTOR Inhibitor NVP-BEZ235 Leads to a Synergistic Enhancement of Cisplatin and Radiation in Both HPV-Negative and -Positive HNSCC Cell Lines

Dual PI3K/mTOR Inhibitor NVP-BEZ235 Leads to a Synergistic Enhancement of Cisplatin and Radiation in Both HPV-Negative and -Positive HNSCC Cell Lines

Head and neck cancers (HNSCCs), especially in the advanced stages, are predominantly treated by radiochemotherapy, including cisplatin. The cure rates are clearly higher for HPV-positive HNSCCs when compared to HPV-negative HNSCCs. For both entities, this treatment is accompanied by serious adverse...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Prif Awduron: Subtil, Florentine S. B., Gröbner, Carolin, Recknagel, Niklas, Parplys, Ann Christin, Kohl, Sibylla, Arenz, Andrea, Eberle, Fabian, Dikomey, Ekkehard, Engenhart-Cabillic, Rita, Schötz, Ulrike
Fformat: Erthygl
Iaith:Saesneg
Cyhoeddwyd: Philipps-Universität Marburg 2023
Pynciau:
Medizin
HPV
NVP-BEZ235
clonogenic survival
cisplatin
HNSCC
radiosensitization
irradiation
Medical sciences Medicine
Mynediad Ar-lein:Testun PDF llawn
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!
Publikationen im Open Access gefördert durch die UB

Eitemau Tebyg